NEW YORK, Feb. 28, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS) announces Dr. Daniel G. Chain, Chairman and CEO, will present at the Bio-Europe Spring Conference March 11-13, 2012 at the Centre Convencions Internacional in Barcelona, Spain. Dr. Chain's presentation, which begins at 10:00 am local time on March 12 th, features the company's CONJUMAB platform technology, including its lead compound, CONJUMAB-A, an antibody drug conjugate being developed for age-related macular degeneration (AMD) as well as the company's tau antibody technology. Dr. Chain will also be attending the 11 th Annual Conference on Alzheimer's disease and Parkinson's disease from March 6-10 in Florence, Italy. "We discovered a novel way to attack certain types of complex diseases through the use of antibody drug conjugates (ADCs) in which two different molecules - an antibody targeting an amyloidogenic polypeptide and a small neuroprotective molecule - are combined chemically into a single entity," said Dr. Daniel Chain, the inventor of CONJUMAB. "The antibody has a chaperone-like role in clearing the amyloid while the small molecule reduces the neurotoxicity caused by the peptide. Our lead drug candidate CONJUMAB-A, capitalizes on recent insights linking the mechanisms that contribute to the pathogenesis of AMD and Alzheimer's disease, especially the role of oxidative stress and amyloid beta (Aβ) which is believed to be an essential mediator in the progression of dry AMD to wet AMD." Traditionally, ADCs have been used to deliver a cytotoxic payload to kill cancer cells. By contrast, drugs based on CONJUMAB are comprised of antibodies targeting amyloidogenic polypeptides that would be linked chemically to a small molecule that is non-toxic and instead confers cytoprotective properties such as an antioxidant or anti-inflammatory molecule. CONJUMAB-A is comprised of a humanized monoclonal antibody against beta amyloid (Aβ) conjugated to melatonin, a potent antioxidant molecule with anti-amyloidogenic, anti-inflammatory and anti-apoptotic properties with the aim of preventing the accumulation of toxic Aβ in the retina and delivering on-site neuroprotection to reduce geographical atrophy and neovascularization.
About Intellect NeurosciencesIntellect Neurosciences, Inc. develops innovative approaches aimed at arresting or preventing Alzheimer's disease and other neurodegenerative diseases, with a specific focus on proteinopathies. Intellect's pipeline includes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates. For more information, please visit www.intellectns.com. The Intellect Neurosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=14741 Safe Harbor Statement Regarding Forward-Looking Statements: The statements in this release and oral statements made by representatives of Intellect Neurosciences relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those discussed in Intellect's Quarterly Report on Form 10-Q (file no. 333-128226), filed on February 12, 2013 and the risk factors discussed under the caption "Risk Factors" in Intellect's Annual Report on Form 10-K (file no. 333-128226), filed on October 15, 2012.
CONTACT: Jules Abraham JQA Partners, LLC 917-885-7378 firstname.lastname@example.org